Industry News

Hill-Rom Holdings, Inc., a global medical technology company, today announced its commitment to add over 100 new jobs at its Welch Allyn subsidiary's facilities in Skaneateles Falls, NY. The commitment, which will bring additional manufacturing, marketing and research and development jobs to the area, comes one year after Hill-Rom acquired Welch Allyn, which is based in Central New York and has maintained a significant presence..."/>
Hill-Rom Adding More Than 100 Jobs In Central New York
Thermo Fisher Scientific and Dr. Schar USA Inc. have awarded Wake Forest Baptist Medical Center in Winston-Salem, North Carolina a $20,000 grant to help fund a one-day family screening event on Saturday, October 22, 2016 where biological relatives of celiac disease patients will be offered free blood testing. Celiac disease is a serious autoimmune condition with a genetic component, affecting just under one percent of the..."/>
Celiac Disease Screening Program to Improve Awareness, Education and Diagnosis Nationwide
UnitedHealth Group, are taking immediate action to help people in Iowa who may be affected by the recent flooding. This includes assisting health plan participants who may need to make alternate..."/>
UnitedHealthcare and Optum Support People Affected by Floods in Iowa
NeuroMetrix, Inc. announced that Frank McGillin, Senior Vice President and General Manger, Consumer, will participate in a panel discussion on the THE DIGITAL HEALTHCARE REVOLUTION at the Wearable Technology Show in Santa Clara, CA on October 5 th. McGillin joins other industry leaders on the panel including Mark Prince, VP Consumer, Withings; Christine Lemke, Co-Founder& President, Evidation Health; and Manish Shah, CEO& Co-Founder, PeerWell."/>
NeuroMetrix Announces Frank McGillin Will Speak at the 2016 Wearable Technology Show
OurVetSuccess Launches 2016 Power Triumph Games
Molina Healthcare, Inc. today announced that it will report its earnings for the third quarter ended September 30, 2016, after the market closes on Thursday, October 27, 2016. The Company’ s management will host a conference call and webcast to discuss the earnings release at 5:00 p.m. Eastern time on the same day.. The number to call for the interactive teleconference is 231-2903. A telephonic replay of the conference call will be available from..."/>
Molina Healthcare Announces Third Quarter 2016 Earnings Release and Conference Call Date
Cannabis Science, Inc., a U.S. company specializing in the development of cannabis-based medicines, is pleased to announce Cannabis Science launches new medicinal product lines for self-medicating patients via legal dispensaries and delivery within the State of California. The new CBIS medicinal product lines are being released based on patient usage data and general public opinion. The Company works with leading experts in drug development, medicinal..."/>
Cannabis Science Launches New Medicinal Product Line in Legal Dispensaries Within the State of California for Self-Medicating Patients
Bionor Pharma ASA. Following these transactions and issuance of the new shares in the Rights Offering Lars Høie holds 121,453,370 shares, equalling 8.76% of the then issued share capital. Lars Høie further owns 15,253,370 warrants in the Company."/>
Bionor Pharma ASA - Mandatory notification of trade - Lars Høie
Teladoc’ s industry leadership and continued expansion. LEWISVILLE, Texas---- Teladoc, Inc., the nation’ s leading provider of telehealth services, today announced that Mark Hirschhorn has been appointed to the newly created role of chief operating officer, while continuing to serve as the company’ s chief financial officer. The new role, and expansion of Mr."/>
Teladoc Names Hirschhorn Chief Operating Officer
Theratechnologies Inc. today announced that it will move forward with the development of the F4 single vial formulation instead of the 2 mg/vial presentation. The introduction of a single vial presentation was part of commitments required by the FDA when it approved EGRIFTA ®. Theratechnologies proposed that the development of the F4 single vial formulation be pursued in replacement of the current 2 mg/vial presentation, and the FDA allowed us to..."/>
Theratechnologies to Move Forward With Development of New Single Vial Formulation for EGRIFTA(R) (Tesamorelin for Injection)
Aurobindo Pharma Ltd became the latest Indian generic maker to get US Food and Drug Administration approval to launch zoledronic acid injection of 4 mg/5ml strength. The medicine, used to treat osteoporosis in women after menopause, is a generic version of Swiss pharmaceutical company Novartis AG's Zometa injection. Aurobindo's zoledronic acid injection is available in a single-use vial for intravenous infusion."/>
BRIEF: Aurobindo Pharma gets USFDA nod for injection to treat osteoporosis [Mint, New Delhi]
Synergy Pharmaceuticals Inc. today announced that the company will present new data on plecanatide, an investigational compound for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation, at the American College of Gastroenterology annual scientific meeting at The Venetian in Las Vegas, October 14-19, 2016.. The following two posters will be presented in Hall C on Monday, October 17th from 10:30 a.m. -4: 00 p.m."/>
Synergy Pharmaceuticals Announces New Plecanatide Data Presentations at Upcoming Scientific Meeting and Provides Update on IBS-C Program
Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced the pricing of an underwritten public offering of 6,000,000 ordinary shares at a price to the public of $9.50 per share. Of the ordinary shares, 5,700,000 shares will be sold by Foamix and 300,000..."/>
Foamix Pharmaceuticals Ltd. Announces Pricing of its $57 Million Follow-on Offering of Ordinary Shares
Versartis, Inc., an endocrine-focused biopharmaceutical company that is developing somavaratan, a novel, long-acting form of recombinant human growth hormone for growth hormone deficiency, today announced the pricing of an underwritten public offering of 4,898,000 shares of its common stock at a public offering price of $12.25 per share. In addition, Versartis has granted the underwriters a 30- day option to purchase up to 734,700 additional..."/>
Versartis Announces Pricing of Follow-On Offering
INVO Bioscience, Inc., a reproductive medical device company who was granted FDA clearance for the first in vivo, vaginal incubation system, the INVOcell™, today announced their partnership to offer the INVO Procedure in the state of California with the renowned CA medical teaching institution, UCSF. "A Simpler Way to Life," the patented INVO™ Procedure, is a fertility treatment solution that streamlines care, contributing to lower treatment..."/>
INVO Bioscience™ Announces One of the World's Leading Health Sciences Universities, the University of California, San Francisco (UCSF) to Offer the Recently FDA Cleared INVOcell™ Intravaginal Culture System
Chembio Diagnostics, Inc., a leader in point-of-care diagnostic tests for infectious diseases, today announced that the Company has been awarded a $330,000 contract by the U.S. Centers for Disease Control and Prevention for the purchase of POC surveillance diagnostic assays for Zika, Dengue and Chikungunya. Under the terms of the 12- month contract, Chembio will provide its DPP ® Zika IgM/IgG Assay, DPP ® Zika/Chikungunya/Dengue IgM/IgG..."/>
Chembio Awarded CDC Contract for Zika, Dengue, and Chikungunya Surveillance Testing in India, Peru, Guatemala and Haiti
Medivation common stock expired as scheduled one minute after 11:59 p.m., Eastern time, on September 27, 2016 Pfizer and Medivation begin joint operations on September 28, 2016 Combined expertise accelerates Pfizer’ s leadership in Oncology, bringing much-needed new cancer treatments to patients Expected to be immediately accretive to Pfizer’ s Adjusted Diluted EPS upon closing, approximately $0.05 accretive in first..."/>
Pfizer Completes Acquisition of Medivation
Invitae Corporation, a genetic information company, is participating in the National Society of Genetic Counselors 35th Annual Education Conference in Seattle, highlighting new research on genetic testing for preventive care and new strategies for providing remote access to genetic counseling services. NSGC is the largest scientific session for genetic counselors. Invitae’ s presenters will discuss:."/>
Invitae Presenting Research on Genetic Test Panels, Increasing Access to Genetic Counseling at the National Society of Genetic Counselors 35th Annual Education Conference
Cardinal Health plans to release first-quarter financial results for its fiscal year 2017 on Oct. 31 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern. To access the webcast and corresponding slide presentation, go to the Investor Relations page at"/>
Cardinal Health to Webcast Discussion of First-Quarter Results for Fiscal Year 2017 on Oct. 31
Neurotrope, Inc., a company focused on developing drugs to treat neurodegenerative diseases including Alzheimer's disease, today announced that it has appointed its Chief Scientific Officer, Dr. Daniel Alkon, to the additional role of President. After approximately 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another approximately 15 years as the Founding..."/>
Dr. Daniel Alkon Appointed President of Neurotrope, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology620 Articles
Consumer Discretionary525 Articles
Financials360 Articles
Industrials337 Articles
Health Care316 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at